Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AdAlta Ltd. ( (AU:1AD) ) has provided an update.
AdAlta Ltd. has announced the quotation of 64,609,961 ordinary fully paid securities and 32,304,981 options expiring in June 2028 on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, potentially enhancing the company’s financial flexibility and market presence, which may positively impact its strategic initiatives and stakeholder value.
More about AdAlta Ltd.
AdAlta Ltd. operates within the biotechnology industry, focusing on the development of novel therapeutic products. The company is known for its proprietary i-body technology, which is utilized in creating treatments for fibrotic diseases and cancer.
Average Trading Volume: 1,060,063
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$2.52M
See more insights into 1AD stock on TipRanks’ Stock Analysis page.